1036915-08-8Relevant articles and documents
Scalable synthesis of a nucleoside phosphoramidate prodrug inhibitor of HCV NS5B RDRP: Challenges in the production of a diastereomeric mixture
Mayes, Benjamin A.,Wang, Jingyang,Arumugasamy, Jeevanandam,Arunachalam, Kannan,Baloglu, Erkan,Bauer, David,Becker, Alan,Chaudhuri, Narayan,Glynn, Roberta,Latham, G. Mark,Li, Jie,Lim, Jinsoo,Liu, Jia,Mathieu, Steve,McGarry, F. Patrick,Rosinovsky, Elodie,Soret, Adrien F.,Stewart, Alistair,Moussa, Adel
, p. 520 - 530 (2015/04/27)
A scalable process is described for the synthesis of 2′-C-methylguanosine-5′-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl-N-benzylphosphoramidate], a nucleotide prodrug inhibitor of hepatitis C virus NS5B polymerase. The route features the use of ph
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
-
Page/Page column 176, (2008/12/07)
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.